

amended in connection with the rulemaking to fully implement mandated electronic filing on the EDGAR system for registrants whose filings are processed by the Divisions of Corporation Finance and Investment Management and for those making filings with respect to such registrants. Development and implementation of the EDGAR system was effected pursuant to Section 35A of the Securities Exchange Act of 1934 (15 U.S.C. 781l).

#### Need for Corrections

This action is necessary to correct an internal cross reference within Form 8-A, for registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. 15 U.S.C. 781(b) or (g).

#### Correction of Publication

Accordingly, the publication on December 30, 1994 of the final EDGAR rules, which were the subject of FR Doc. 94-31579, is corrected as follows:

1. On page 67765, second column, the amendatory language for amendment No. 35 is corrected to read as follows:

“35. By amending Form 8-A (referenced in § 249.208a), Instruction II.2 of Instructions as to Exhibits, by revising the phrase ‘pursuant to Instruction 3 above’ to read ‘pursuant to Instruction II.1, above.’”

Dated: January 9, 1995.

**Margaret H. McFarland,**

*Deputy Secretary.*

[FR Doc. 95-912 Filed 1-12-95; 8:45 am]

BILLING CODE 8010-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### 21 CFR Part 520

#### Oral Dosage Form New Animal Drugs; Neomycin Sulfate Oral Solution

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Phoenix Scientific, Inc. The ANADA provides for use of a generic neomycin sulfate oral solution in the drinking water and milk for cattle (excluding veal calves), swine, sheep, and goats for the treatment and control of colibacillosis. **EFFECTIVE DATE:** January 13, 1995.

**FOR FURTHER INFORMATION CONTACT:** Melanie R. Berson, Center for Veterinary Medicine (HFV-135), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1643.

**SUPPLEMENTARY INFORMATION:** Phoenix Scientific, Inc., 3915 South 48th St. Terrace, P.O. Box 6457, St. Joseph, MO 64506-0457, filed ANADA 200-118, which provides for the use of neomycin oral solution (neomycin sulfate) in the drinking water and milk for cattle (excluding veal calves), swine, sheep, and goats for the treatment and control of colibacillosis (bacterial enteritis) caused by *Escherichia coli* susceptible to neomycin sulfate. Approval of ANADA 200-118 is as a generic copy of the Upjohn Co.'s approved NADA 11-315. The ANADA is approved as of November 29, 1994, and 21 CFR 520.1485(b) is amended to reflect the approval. The basis for approval is discussed in the freedom of information summary.

In addition, the heading of the section is editorially revised to reflect the name of the product.

In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and § 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

#### List of Subjects in 21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

#### PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as follows:

**Authority:** Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

2. Section 520.1485 is amended by revising the section heading and paragraph (b) to read as follows:

#### § 520.1485 Neomycin sulfate oral solution.

\* \* \* \* \*

(b) *Sponsors.* See Nos. 000009 and 059130 in § 510.600(c) of this chapter.

\* \* \* \* \*

Dated: January 3, 1995.

**Stephen F. Sundlof,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 95-899 Filed 1-12-95; 8:45 am]

BILLING CODE 4160-01-F

## 21 CFR Part 558

### New Animal Drugs For Use In Animal Feeds; Salinomycin In Combination

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the approval of three abbreviated new animal drug applications (ANADA's) filed by Hoechst-Roussel Agri-Vet Co. The ANADA's provide for using approved Type A medicated articles to make Type C medicated broiler feeds containing salinomycin with chlortetracycline and roxarsone, or salinomycin with chlortetracycline, or salinomycin with oxytetracycline.

**EFFECTIVE DATE:** January 13, 1995.

**FOR FURTHER INFORMATION CONTACT:** Melanie R. Berson, Center for Veterinary Medicine (HFV-135), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1643.

**SUPPLEMENTARY INFORMATION:** Hoechst-Roussel Agri-Vet Co., P.O. Box 2500, Somerville, NJ 08876-1258, filed the following ANADA's:

ANADA 200-091, salinomycin with chlortetracycline and roxarsone, which provides for using approved single ingredient Type A medicated articles to make Type C medicated broiler feeds containing 40 to 60 grams per ton (g/t) salinomycin sodium activity, chlortetracycline calcium complex equivalent to 500 g/t chlortetracycline hydrochloride, and 45.4 g/t roxarsone for prevention of coccidiosis and as an aid in reduction of mortality due to certain *Escherichia coli* infections.

ANADA 200-095, salinomycin with chlortetracycline, which provides for using approved single ingredient Type A medicated articles to make Type C medicated broiler feeds containing 40 to 60 g/t salinomycin sodium activity with